Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Patrick SchöffskiDaniel S W TanMiguel MartínMaría Ochoa-de-OlzaJohn SarantopoulosRichard D CarvajalChrisann KyiTaito EsakiAmy PrawiraWallace AkerleyFilippo De BraudRina HuiTian ZhangRoss A SooMichela MaurAndrew WeickhardtJürgen KraussBarbara Deschler-BaierAllen LauTanay S SamantTyler LongmireNiladri Roy ChowdhuryCatherine A Sabatos-PeytonNidhi PatelRadha RameshTiancen HuAna CarionDaniel GusenleitnerPadmaja Yerramilli-RaoVasileios AskoxylakisEunice L KwakDavid S HongPublished in: Journal for immunotherapy of cancer (2022)
NCT02460224.
Keyphrases